Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30986710 | 1.00 | TSHR (0.58) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL477602 | 0.87 | ACP3 (0.53) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL477580 | 0.87 | ACP3 (0.53) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL29609159 | 0.87 | ACP3 (0.53) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL11641801 | 0.84 | ESR2 (0.46) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL5753910 | 0.84 | IGF1R (0.43) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL6001430 | 0.84 | ATM (0.47) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL29976363 | 0.82 | ADRB2 (0.48) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL230382 | 0.82 | ADRB2 (0.48) | TSHRHIF1ACNR1SLC6A2SLC6A4 | |
| SCHEMBL6564634 | 0.80 | CNR2 (0.45) | TSHRHIF1ACNR1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702041-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | Chiesi Farmaceutici S.p.A. (IT) | 2014-03-05 | — | — | EP | disclosed |
| US-8604015-B2 | Alkaloid ester and carbamate derivatives and medicinal compositions thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-12-10 | — | — | US | disclosed |
| WO-2012146515-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-11-01 | — | — | WO | disclosed |
| US-20120276018-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-11-01 | — | — | US | disclosed |
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | VERNALIS RESEARCH LIMITED. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-7504522-B2 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | VERNALIS RESEARCH LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | VERNALIS RESEARCH LIMAITED (GB) | 2007-03-08 | — | — | US | disclosed |
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-0781749-B1 | Process for producing optically active benzhydrol compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-H2007-H1 | INSECTICIDES | FMC CORPORATION | 2001-12-04 | — | — | US | disclosed |
| US-5780692-A | CATALYTIC ASYMMETRIC HYDROGENATION OF A BENZOPHENONE; SIMPLIFICATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1998-07-14 | — | — | US | disclosed |
| WO-1997026252-A1 | INSECTICIDAL N-HETEROCYCLYLALKYL- OR N-[(POLYCYCLYL)-ALKYL]-N'-SUBSTITUTED PIPERAZINES | FMC CORPORATION (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0781749-A2 | Process for producing optically active benzhydrol compounds | Takasago International Corporation (JP) | 1997-07-02 | — | — | EP | disclosed |
| US-4225723-A | Process for the preparation of substituted arylcyanoalkyl and diaryl cyanoalkylimidazoles | ROHM AND HAAS COMPANY (US) | 1980-09-30 | — | — | US | disclosed |
| US-4143137-A | SUBSTITUTED ARYLCYANOALKYL AND DIARYLCYANOALKYLIMIDAZOLE METAL SALT COMPLEXES AND FUNGICIDAL COMPOSITIONS AND METHODS UTILIZING THEM | ROHM AND HAAS COMPANY (US) | 1979-03-06 | — | — | US | disclosed |
| US-4073921-A | FUNGICIDES | ROHM AND HAAS COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276018-A1 | ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | CHRM3, BCHE, CHRM1 | TSHR 3024/4885HIF1A 569/4885CNR1 26/4885 |
| US-20070054891-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders | CNR1, CNR2, GPR119 | TSHR 368/4885HIF1A 1247/4885CNR1 1/4885 |
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | CNR1, CNR2, GPR119 | TSHR 404/4885HIF1A 2339/4885CNR1 1/4885 |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | CNR1, CNR2, GPR119 | TSHR 121/4885HIF1A 1932/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.